Literature DB >> 23768057

Predictive factors influencing facial nerve outcomes in surgery for small-sized vestibular schwannoma.

Jae-Hyun Seo1, Beom-Cho Jun, Eun-Ju Jeon, Ki-Hong Chang.   

Abstract

CONCLUSION: The most important predictive factor of facial nerve outcome in surgery for small-sized vestibular schwannoma (VS) is the adhesion between the tumor and the facial nerve.
OBJECTIVES: To compare the facial nerve outcomes between middle cranial fossa (MCF) and translabyrinthine (TL) approaches, and to analyze the preoperative and intraoperative factors influencing facial nerve outcome after small VS surgery in our neurotologic department.
METHODS: A total of 29 patients were retrospectively analyzed, with 16 in the MCF group and 13 in the TL group. Facial function was serially evaluated according to the House-Brackmann classification at 7 days, 1 month, 3 months, 6 months, and 1 year postoperatively. The effects of variables such as the surgical approach, tumor size, nerve origin, extrameatal extension, intraoperative tumor adhesion to the facial nerve, and facial nerve displacement were determined.
RESULTS: Early and late facial nerve outcomes showed no significant correlation with surgical approach, tumor origin, tumor size, extrameatal extension, or facial nerve displacement pattern. However, a significant correlation was observed with tumor adhesion to the facial nerve and facial nerve outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23768057     DOI: 10.3109/00016489.2013.776178

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Facial Nerve Adherence in Vestibular Schwannomas: Classification and Radiological Predictors.

Authors:  Gustavo Simiano Jung; Guilherme Ramina Montibeller; Gabriel Schier de Fraga; Thais Dos Santos Rohde; Ricardo Ramina
Journal:  J Neurol Surg B Skull Base       Date:  2020-07-01

2.  Analysis of Related Factors Affecting Facial Nerve Function after Acoustic Neuroma Surgery.

Authors:  Chunhan Liu; Yage Shen; Dongyi Han; Di Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-09       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.